Abstract:BACKGROUND: High-density lipoprotein (HDL) plays an antiatherogenic role by mediating reverse cholesterol transport (RCT), antioxidation, anti-inflammation, and endothelial cell protection. Recently, series of evidence have shown that HDL can also convert to proatherogenic HDL under certain circumstances. Plasma paraoxonase 1 (PON1) as an HDL-bound esterase, is responsible for most of the antioxidant properties of HDL. However, whether PON1 can serve as a therapeutic target of dysfunctional HDL-related atherosclerosis remains unclear.METHODS: In this study, scavenger receptor class B type I deficient (Scarb1-/- ) mice were used as the animal model with dysfunctional HDL and increased atherosclerotic susceptibility. Hepatic PON1 overexpression and secretion into circulation were achieved by lentivirus injection through the tail vein. We monitored plasma lipids levels and lipoprotein profiles in Scarb1-/- mice, and measured the levels and activities of proteins associated with HDL function. Meanwhile, lipid deposition in the liver and atherosclerotic lesions was quantified. Hepatic genes relevant to HDL metabolism and inflammation were analyzed.RESULTS: The results showed the relative levels of PON1 in liver and plasma were increased by 1.1-fold and 1.6-fold, respectively, and mean plasma PON1 activity was increased by 63%. High-level PON1 increased the antioxidative and anti-inflammatory properties, promoted HDL maturation and macrophage cholesterol efflux through increasing HDL functional proteins components apolipoprotein A1 (APOA1), apolipoprotein E (APOE), and lecithin-cholesterol acyltransferase (LCAT), while decreased inflammatory protein markers, such as serum amyloid A (SAA), apolipoprotein A4 (APOA4) and alpha 1 antitrypsin (A1AT). Furthermore, hepatic PON1 overexpression linked the effects of antioxidation and anti-inflammation with HDL metabolism regulation mainly through up-regulating liver X receptor alpha (LXRα) and its downstream genes. The pleiotropic effects involved promoting HDL biogenesis by raising the level of APOA1, increasing cholesterol uptake by the liver through the APOE-low density lipoprotein receptor (LDLR) pathway, and increasing cholesterol excretion into the bile, thereby reducing hepatic steatosis and aorta atherosclerosis in Western diet-fed mice.CONCLUSIONS: Our study reveals that high-level PON1 improved dysfunctional HDL and alleviated the development of atherosclerosis in Scarb1-/- mice. It is suggested that PON1 represents a promising target of HDL-based therapeutic strategy for HDL-related atherosclerotic cardiovascular disease.

Paraoxonase 1 Ameliorates Renal Lipotoxicity by Activating Lipophagy and Inhibiting Pyroptosis

Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development

Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer

Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice

The Molecular Bases of Anti-Oxidative and Anti-Inflammatory Properties of Paraoxonase 1

PPAR-<i></i> Activation Alleviates Osteoarthritis through Both the Nrf2/NLRP3 and PGC-1<i></i>/<i></i><sub>m</sub> Pathways by Inhibiting Pyroptosis

Single Intravenous Injection of Plasmid DNA Encoding Human Paraoxonase-1 Inhibits Hyperlipidemia in Rats

Paraoxonase 2 protects against acute myocardial ischemia-reperfusion injury by modulating mitochondrial function and oxidative stress via the PI3K/Akt/GSK-3β RISK pathway

Osteopontin Acts As a Negative Regulator of Autophagy Accelerating Lipid Accumulation During the Development of Nonalcoholic Fatty Liver Disease

Paraoxonases Function As Unique Protectors Against Cardiovascular Diseases and Diabetes: Updated Experimental and Clinical Data.

The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Protective Effect of Paraoxonase 1 of High‐density Lipoprotein in Type 2 Diabetic Patients with Nephropathy

Paraoxonase 2 (PON2) Deficiency Reproduces Lipid Alterations of Diabetic and Inflammatory Glomerular Disease and Affects TRPC6 Signaling

Transgene Expression of Human Paraoxonase 1 Q (hPON1Q) Protects the Liver against CCl4-induced Injury

Studies on Protective Effects of Human Paraoxonases 1 and 3 on Atherosclerosis in Apolipoprotein E Knockout Mice.

Involvement of Xanthine Oxidase and Paraoxonase 1 in the Process of Oxidative Stress in Nonalcoholic Fatty Liver Disease.

Paraoxonase-1 Is a Pivotal Regulator Responsible for Suppressing Allergic Airway Inflammation Through Adipose Stem Cell-Derived Extracellular Vesicles

Transgene Expression of Human PON1 Q in Mice Protected the Liver Against CCl4-induced Injury.

PON2 ameliorates Ang II‐induced cardiomyocyte injury by targeting the CANX/NOX4 signaling pathway

Paraoxonase 2 protects against the CML mediated mitochondrial dysfunction through modulating JNK pathway in human retinal cells

Dopamine D1 and D5 Receptors Differentially Regulate Oxidative Stress Through Paraoxonase 2 in Kidney Cells.